Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Which FLT3 Inhibitor for Treatment of AML?

Current treatment options in oncology - 1 Mar 2022

Senapati Jayastu, Kadia Tapan Mahendra

Abstract excerpt

OPINION STATEMENT: Treatment options in acute myeloid leukemia (AML) have improved significantly over the last decade with better understanding of disease biology and availability of a multitude of targeted therapies. The use of FLT3 inhibitors (FLT3i) in FLT3-mutated (FLT3mut) AML is one such development; however, the clinical decisions that govern their use and dictate the choice of the FLT3i are evolving....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to fms-Like Tyrosine Kinase 3
Share to Hematopoietic Stem Cell Transplantation
Share to Leukemia, Myeloid, Acute

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Transplantation, Homologous

Source

Identifiers

PMID: 35258791
DOI: 10.1007/s11864-022-00952-6

Genes

SCT
FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Which FLT3 Inhibitor for Treatment of AML?PMID 35258791Read ↗

FLT3-targeted treatment for acute myeloid leukemia.Semantic proximity Read ↗

FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.Semantic proximity Read ↗

FLT3 Inhibitors for Treating Acute Myeloid Leukemia.Semantic proximity Read ↗

FMS-Like Tyrosine Kinase 3 Inhibitors for the Treatment of Acute Myeloid Leukemia.Semantic proximity Read ↗

FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.Semantic proximity Read ↗

A review of FLT3 inhibitors in acute myeloid leukemia.Semantic proximity Read ↗

Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia.Semantic proximity Read ↗

Safety of FLT3 inhibitors in patients with acute myeloid leukemia.Semantic proximity Read ↗

FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review.Semantic proximity Read ↗

Targeting FMS-like tyrosine kinase 3 (FLT3) in acute myeloid leukemia: Novel molecular approaches and therapeutic challengesSemantic proximity Read ↗

[Current status and challenges of AML treatment with FLT3 inhibitors].Semantic proximity Read ↗

Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel ApproachesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.